Table 2.
Procedural characteristics of PS-matched cohort; n (%) if not otherwise specified
| Perioperative outcomes in PS-matched cohort (n = 27) | |||
|---|---|---|---|
| HM3 + FMR (n = 27) | HM3 + TMR (n = 27) | p value | |
| Time frame between TMR implantation and LVAD implantation | - | 26 months (3.5–26; range, 0–85) | - |
| Surgical access | |||
| Median sternotomy | 27 (100) | 26 (96) | 1 |
| Lateral thoracotomy | 0 (0) | 1 (4) | 1 |
| Additional surgical procedure during LVAD implantation | |||
| Atrial septum defect closure | 2 (7.4) | 16 (59) | < 0.001 |
| Aortic valve replacement | 2 (7.4) | 4 (15) | 0.67 |
| Tricuspid valve repair | 3 (11) | 9 (33) | 0.099 |
| Ascending aorta replacement | 0 (0) | 1 (4) | 1 |
| Left atrial appendage closure | 0 (0) | 4 (15) | 0.11 |
| Perioperative outcomes | |||
| CentriMag implantation | 8 (30) | 7 (26) | 1 |
| Mortality within 30 days | 1 (4, sepsis) | 2 (7.4, MOF) | 1 |
HM, HeartMate 3; TMR, transcatheter percutaneous mitral valve repair; LVAD, left ventricular assist device; MOF, multiple organ failure.